Разработка эффективной опытно-промышленной технологии получения N,N-бисметионилгистона H1.3, используемого для терапии лимфом

At present, much attention is devoted to the treatment of lymphomas by means of monoclonal antibodies. Unfortunately, no preparations such as Rituximab (Mabthera) are produced in the Russian Federation and these have to be imported from abroad. It is shown that H1 type histones possessing an activity similar to that of Rituximab can be used for such a therapy. We have developed an experimental commercial technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in various tests. The accumulated amount of the active pharmaceutical substance is enough to start clinical trials in Russia.